Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Q4 2025 vs. Q3 2025
How the institutions holding Cidara Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 173 | 2 | 255 | +84 |
| Shares | 32.5M | 65.1K | 33.3M | +888.0K (+2.7%) |
| Value | $3.11B | $6.24M | $7.36B | +$4.25B (+136.9%) |
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (139)
Institutions that held Cidara Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
Showing the largest 100 of 139 by value.
Sold out (55)
Institutions that held Cidara Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
Not filed for Q4 2025 yet (2)
Institutions that held Cidara Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| AXA Investment Managers S.A. | 61,154 | $5.86M |
| Bryce Point Capital, LLC | 3,977 | $380.8K |